NIH offers Biological Testing Facility services to advance contraceptive development and reproductive health programs toward regulatory submission or clinical development; current NIH funding is not required.
Funder: National Institutes of Health
Due Dates: January 4, 2027 (Application) | May 3, 2027 (Application) | September 6, 2027 (Application) | January 3, 2028 (Application) | May 1, 2028 (Application) | September 4, 2028 (Application) | January 2, 2029 (Application) | May 7, 2029 (Application)
Funding Amounts: Resource services, not cash funding; maximum project period of one year; no cost sharing required
Summary: Access Biological Testing Facility services to advance contraceptive and reproductive health products toward regulatory submission and clinical development.
Key Information: Clinical trials are not allowed; defined molecular targets must be validated before application submission.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) offers this X01 Resource Access Award to investigators developing contraceptive methods or reproductive health therapies and devices. It provides access to the Biological Testing Facility (BTF) for preclinical and Investigational New Drug (IND) or Investigational Device Exemption (IDE)-enabling studies, rather than financial support to applicants. The goal is to advance safe, effective products while understanding long-term effects on fertility and infertility.
Available services include formulation preparation, fertility studies, pharmacology, toxicology, reproductive tract histopathology, sperm morphology and motility, and pharmacokinetic and ADME studies. Highest priority goes to late-stage preclinical compounds and devices. Chemical hits or leads, and devices with unknown targets or mechanisms of action, are deprioritized.